Browse the evidence

Second-generation incretin receptor agonists (GLP-1 RAs like semaglutide and liraglutide, and dual GLP-1/GIP agonist tirzepatide) significantly reduce blood pressure and promote weight loss in obesity-related hypertension, outperforming first-generation anti-obesity drugs.

For obesity-related hypertension, second-generation incretin receptor agonists (GLP-1 RAs) like semaglutide (2.4 mg weekly) or liraglutide (3 mg daily) are the most effective pharmacological treatments for lowering blood pressure and promoting weight loss. They significantly outperform older anti-obesity drugs. These medications should be integrated with lifestyle changes (diet and exercise) and are particularly effective in non-diabetic obese patients, though they also benefit those with type 2 diabetes.

GLP-1 receptor agonists (semaglutide, liraglutide) produce significantly greater weight loss than lifestyle modifications alone and are superior to older agents like orlistat and liraglutide (1.8mg).

If lifestyle changes alone haven't worked, GLP-1 agonists like semaglutide are highly effective. They work by mimicking a hormone that controls hunger. You take a weekly injection. Expect some stomach issues initially, but they often subside. These drugs are significantly more effective than older options like orlistat.

GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 receptor agonists (GIP/GLP-1 RAs) significantly reduce body weight and improve metabolic health in individuals with obesity and type 2 diabetes.

If you have obesity or type 2 diabetes, GLP-1 and GIP/GLP-1 medications (like semaglutide or tirzepatide) are highly effective for weight loss and improving metabolic health. These drugs work by mimicking gut hormones to reduce appetite and improve insulin sensitivity. To get the best results and minimize side effects, start with a low dose and increase it slowly. It is also crucial to combine medication with lifestyle changes, specifically focusing on strength training and eating enough protein to protect your muscles from being lost along with fat.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) provide greater weight reduction and better metabolic control compared to GLP-1 receptor mono-agonists.

If you are not achieving sufficient weight loss with a GLP-1 medication like semaglutide, switching to a dual GIP/GLP-1 agonist like tirzepatide may offer greater benefits. Clinical trials show that tirzepatide can lead to even more significant weight loss compared to existing GLP-1 drugs. This makes it a strong option for those who need more aggressive treatment.

Tirzepatide significantly reduces apnea-hypopnea index (AHI) and resolves obstructive sleep apnea (OSA) in obese patients, with approximately 50% achieving resolution after 52 weeks of treatment.

If you have obesity and OSA, tirzepatide (10-15mg weekly) can significantly reduce your apnea severity and may even resolve OSA in half of users after one year. It is not a quick fix; it takes time to lose weight. For severe cases, it should be used alongside CPAP initially, with the goal of potentially reducing CPAP dependence as weight loss occurs. Long-term use is likely necessary to maintain benefits.

GLP-1 receptor agonists (specifically semaglutide and tirzepatide) significantly improve cardiovascular outcomes, symptoms, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, primarily through substantial weight loss and metabolic improvement.

If you have HFpEF and are obese, GLP-1 medications like semaglutide or tirzepatide are now proven to help your heart, reduce symptoms, and improve your quality of life. The key is that this is intentional weight loss, which is different from the involuntary weight loss seen in advanced heart failure. Discuss these options with your cardiologist, as they can significantly reduce your risk of hospitalization and cardiovascular death.

GLP-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide produce clinically significant weight loss (15-22.5%) and cardiovascular risk reduction, serving as a scalable pharmacological adjunct to lifestyle interventions.

GLP-1 RAs like semaglutide and tirzepatide are highly effective medications for weight loss, producing 15-22% body weight loss in clinical trials. They work by mimicking gut hormones to reduce appetite and improve metabolic health. They are not a 'magic bullet' but a tool that works best when combined with dietary changes, physical activity, and psychological support. Common side effects like nausea are usually temporary and manageable. These drugs are particularly useful for those who have struggled with long-term weight maintenance through lifestyle changes alone.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce significantly greater weight loss (10-20%+) compared to other anti-obesity medications (3-7%) and placebo.

If lifestyle changes are not enough, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Mounjaro) offer the highest weight loss potential (10-20%). These are injectable medications typically used when BMI is >30 (or >27 with comorbidities). They work by reducing appetite and slowing digestion. Consult a physician to see if you qualify.

Pharmacological treatment with Semaglutide (2.4 mg) achieves clinically relevant weight loss (~16%) regardless of the intensity of concurrent lifestyle interventions.

Take Semaglutide 2.4 mg once weekly. While you should still try to eat slightly less and move more, do not expect these lifestyle changes to drive your weight loss. The medication does the heavy lifting by correcting your biology. Expect ~16% weight loss over 68 weeks.

GLP-1 receptor agonists (GLP-1RAs) and dual GIP/GLP-1 agonists (e.g., tirzepatide) provide superior glycemic control and significant body weight reduction compared to standard therapies, establishing them as cornerstone treatments for type 2 diabetes and obesity.

If you have Type 2 Diabetes or Obesity, GLP-1 and dual-agonist medications are now considered cornerstone treatments that offer better blood sugar control and weight loss than older therapies, especially if you have heart or kidney risks. These drugs work by mimicking gut hormones to increase insulin, slow digestion, and reduce appetite. While they can cause stomach issues, starting with a low dose and slowly increasing it helps your body adjust. Oral versions are available for some drugs, removing the need for injections for those who prefer it.

Second-generation obesity medications (semaglutide 2.4 mg and tirzepatide) achieve clinically significant weight loss (≥15% body weight) and treat or prevent obesity-related complications, establishing a complications-centric approach to care.

If you have obesity, especially with complications like diabetes or heart disease, second-generation medications like semaglutide or tirzepatide are now available that can help you lose 15% or more of your body weight. This level of weight loss is significant enough to improve or prevent many serious health issues. The main barrier is often cost and insurance coverage, so advocate for your access to these treatments as a medical necessity.

Weekly subcutaneous semaglutide (2.4 mg) significantly reduces body weight and major adverse cardiovascular events in non-diabetic patients with obesity and established cardiovascular disease.

If you have obesity and existing heart disease, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly reduce your body weight and lower your risk of heart attacks, strokes, and death, offering strong protection for your heart.

Semaglutide 2.4 mg subcutaneous once weekly significantly reduces body weight and improves cardiovascular risk factors in obese or overweight adults with or without type 2 diabetes.

Semaglutide 2.4 mg injected once weekly, combined with a low-calorie diet and exercise, is a highly effective treatment for weight loss and cardiovascular risk reduction in obese or overweight adults. You must commit to long-term use, as stopping the medication leads to weight regain. Start with a lower dose to minimize stomach side effects, which usually improve over time.

Concomitant administration of ixekizumab (IL-17A inhibitor) and tirzepatide (dual GIP/GLP-1 receptor agonist) achieves significantly greater disease control and weight loss in adults with psoriatic arthritis (PsA) and overweight/obesity compared to ixekizumab monotherapy.

For PsA patients who are overweight or obese, adding tirzepatide to ixekizumab therapy offers a dual benefit: significantly better joint symptom control and substantial weight loss, compared to using ixekizumab alone. This combination addresses both the inflammatory and metabolic aspects of the disease, leading to improved physical function and quality of life, with a safety profile consistent with the individual drugs.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces superior weight loss (up to 20.9%) and visceral fat reduction compared to other anti-obesity medications.

Tirzepatide is currently the most effective pharmacological tool for significant weight loss, capable of reducing body weight by over 20% in clinical trials. It works by mimicking two gut hormones (GLP-1 and GIP) to reduce appetite and fat storage. While highly effective, it requires weekly injections and careful monitoring for gastrointestinal side effects like nausea.

Semaglutide 2.4 mg administered weekly results in a mean weight loss of 14.9% over 68 weeks, significantly outperforming placebo.

Semaglutide 2.4 mg, taken as a weekly injection, is a highly effective treatment for obesity, leading to an average 14.9% weight loss over 68 weeks. It works by mimicking the GLP-1 hormone to increase satiety and reduce appetite. Common side effects include gastrointestinal issues like nausea and diarrhea.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and placebo in patients with obesity.

Tirzepatide (5-15 mg weekly) is a potent option for obesity, achieving up to 21% weight loss in trials. It is a dual GIP/GLP-1 agonist. Consider it if semaglutide is insufficient or not tolerated, provided cost and access allow.

Tirzepatide demonstrates superior weight loss efficacy compared to Semaglutide, achieving an average weight loss of -20.9% at the highest dose (15 mg) in obese patients without type 2 diabetes.

If you are struggling to lose weight with Semaglutide, ask your doctor about Tirzepatide. Clinical trials show it can lead to greater weight loss (around 21%) compared to Semaglutide (around 14%) in obese patients without diabetes. However, be aware that it may be more expensive and less likely to be covered by insurance.

GLP-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce major adverse cardiovascular events (MACE) and heart failure hospitalizations in patients with type 2 diabetes, independent of glycemic control.

If you have Type 2 Diabetes and heart disease or high risk, ask your doctor about GLP-1 RAs or SGLT2is. These drugs protect your heart and kidneys, not just your blood sugar. They are often preferred over older medications like metformin if you have these risks.

Tirzepatide (5-15 mg once weekly) significantly reduces HbA1c (by 1.5-2.5%) and body weight (by 15-25%) in patients with type 2 diabetes and obesity, outperforming standard therapies like semaglutide and insulin.

Tirzepatide is a once-weekly injection approved for T2DM and obesity. It works by mimicking hormones that regulate blood sugar and appetite. Clinical trials show it lowers HbA1c by up to 2.5% and causes significant weight loss (15-25%). It is more effective than semaglutide and insulin for these metrics. Common side effects are gastrointestinal (nausea, diarrhea) but often improve over time. Weight regain is common if the drug is stopped, suggesting long-term use may be necessary for sustained results.

Tirzepatide (dual GIP/GLP-1 agonist) produces significantly greater weight loss and waist circumference reduction than semaglutide (selective GLP-1 agonist) in adults with obesity without diabetes.

If your primary goal is maximum weight loss and you do not have diabetes, tirzepatide (15mg weekly) is clinically superior to semaglutide (2.4mg weekly). While both are effective, tirzepatide yields significantly greater fat loss and waist reduction. Be aware that while tirzepatide may have better GI tolerability, it still carries class-specific risks.

Discontinuation of incretin-based therapies (GLP-1/GIP agonists) consistently leads to rapid and clinically meaningful weight regain, typically recovering two-thirds of lost weight within one year, alongside the reversal of cardiometabolic improvements.

If you stop taking incretin-based weight loss medication, you will likely regain about two-thirds of the weight you lost within a year. This is not a failure of willpower but a biological response to the loss of the drug's hormonal effects. To maintain your weight loss, you likely need to continue the medication long-term or use very aggressive, sustained lifestyle interventions, though even those are often insufficient to prevent significant regain.

GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.

GLP-1 and dual agonists are highly effective for significant weight loss (up to 21%) and diabetes prevention in adults with obesity. They work by targeting hormonal pathways to reduce appetite and improve insulin sensitivity. While effective, they require long-term use to maintain benefits, as stopping leads to significant weight regain. Side effects like nausea and diarrhea are common but manageable, and the choice of agent depends on individual tolerance and specific health goals.

mTORC1 is the central integrator of anabolic signals from both resistance exercise and dietary protein, mediating muscle protein synthesis and hypertrophy.

Understanding mTORC1 is important for researchers but has limited direct practical application for the average person. Focus on the external drivers: lift weights and eat enough protein.